Expansion of the natural killer–cell subset in patients with multiple myeloma receiving treatment with thalidomide
| Patient . | Response to Thal . | Fold change in absolute number of NK cells . | Fold change in percentage of NK cells . |
|---|---|---|---|
| 1 | Partial response | 2.9 | 5.6 |
| 2 | Partial response | 3.9 | 2.8 |
| 3 | Stable | 2.4 | 2.1 |
| 4 | Relapse | 2.4 | 0.6 |
| 5 | Relapse | 1.3 | 1.3 |
| Patient . | Response to Thal . | Fold change in absolute number of NK cells . | Fold change in percentage of NK cells . |
|---|---|---|---|
| 1 | Partial response | 2.9 | 5.6 |
| 2 | Partial response | 3.9 | 2.8 |
| 3 | Stable | 2.4 | 2.1 |
| 4 | Relapse | 2.4 | 0.6 |
| 5 | Relapse | 1.3 | 1.3 |
NK indicates natural killer. See Table 1 for other abbreivations.
Serial phenotypic analysis of peripheral blood NK cell (CD56+) subsets was performed on 5 patients with MM receiving Thal therapy.